COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resistant Starch, Gut Bacteria and Diabetes (RSDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03057444
Recruitment Status : Completed
First Posted : February 20, 2017
Last Update Posted : October 26, 2018
Sponsor:
Collaborator:
Institut für Mikroökologie GmbH
Information provided by (Responsible Party):
University of Hohenheim

Brief Summary:
The aim of the study is to investigate, if resistant starch type III increases butyrate-producing bacteria in the gut of (pre-) diabetic subjects. Diabetic blood parameters are also of interest.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Pre Diabetes Dietary Supplement: SymbioIntest Not Applicable

Detailed Description:

Other studies show that diabetics have less butyrate-producing bacteria species in the gut compared to non-diabetes patients and diabetes patients who are taking metformin. Moreover, studies demonstrate that resistant starch increases the butyrate-producing bacteria species. Furthermore, studies show that butyrate has on effect on blood glucose and insulin homeostasis.

The aim in this study is to investigate, if resistant starch typ III increases butyrate-producing bacteria in the gut of (pre-) diabetic subjects, The effects on blood glucose, insulin and HbA1c are investigated as well.

Patients included in the study are typ 2 diabetics with lifestyle interventions, insulin or antidiabetic medication (sulfonylureas, glinides, SGLT2-inhibitors, glitazone) or pre-diabetics.

They get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.

Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open intervention study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Influence of Resistant Starch Type III on Butyrate-producing Gut Bacteria and Diabetes Parameter in (Pre-) Diabetes
Actual Study Start Date : February 10, 2017
Actual Primary Completion Date : May 31, 2018
Actual Study Completion Date : May 31, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Starch

Arm Intervention/treatment
Experimental: Intervention group

The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.

Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention.

Dietary Supplement: SymbioIntest
The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.




Primary Outcome Measures :
  1. Change of gut bacteria [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week ]
    quantitative Analyse with Next-Generation Sequencing

  2. Change of short chain fatty acid concentration in the gut [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week ]
    gas chromatography


Secondary Outcome Measures :
  1. change from baseline in HbA1c at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week. ]
  2. change from baseline in insulin at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week. ]
  3. change from baseline in blood glucose at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week ]
  4. Change from baseline in anthropometry at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week ]

Other Outcome Measures:
  1. Change from baseline in PYY (Peptide YY) at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week. ]
    with ELISA

  2. Change from baseline in GLP-1 (Glucagon-like peptide-1) at four weeks and eight weeks after consumption resistant starch type III [ Time Frame: Participants will be followed for the time of eight weeks. Examinations take place at baseline, four and eight week. ]
    with ELISA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female adult persons (≥ 18 years)
  • Type 2 diabetes mellitus discontinued with lifestyle interventions or insulin therapy or oral antidiabetic therapy (sulphonylureas, glinides, SGLT-2 (sodium/glucose cotransporter 2) inhibitors, glitazone) or a prediabetic metabolism
  • It is foreseeable that no therapy with metformin or α-glucosidase inhibitors or DPP-4 (Dipeptidyl peptidase-4) inhibitors is initiated during the period of study (8 weeks)
  • willingness not to systematically change diet and lifestyle habits during the study
  • Adequate understanding of the German language and sufficient psychological condition to understand the information and instructions associated with the study and to complete questionnaires and assessment scales
  • Signed informed consent

Exclusion Criteria:

  • Treatment of Type II diabetes mellitus by metformin or α-glucosidase inhibitors or DPP-4 inhibitors
  • Diminished diabetic metabolic position or medical necessity to convert the therapy in the foreseeable future (HbA1c ≥ 7% or fasting glucose ≥ 152 mg / dl)
  • Participation in another clinical trial (currently or within the last 30 days)
  • Incompatibility with the ingredients of the investigational medicinal product
  • Pregnancy or lactation
  • Inability to take the test preparation orally
  • changes in dietary habits and habits within the last 30 days
  • Antibiotics intake currently or within the last 30 days
  • Drug abuse in the last six months before the start of the study or ongoing. Alcohol abuse is defined as an average daily of more than 20 g of alcohol in women and more than 30 g of alcohol in men, based on the last six months
  • A state of health (including abnormal laboratory values) that, at the discretion of the investigator, does not allow study participation, evaluation of study parameters or the use of the investigational medicinal product
  • Accommodation in a clinic or similar facility, by administrative or judicial order

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03057444


Locations
Layout table for location information
Germany
Institute of Clinical Nutrition
Stuttgart, Baden-Württemberg, Germany, 70599
Sponsors and Collaborators
University of Hohenheim
Institut für Mikroökologie GmbH
Investigators
Layout table for investigator information
Principal Investigator: Stephan C. Bischoff, Prof. University of Hohenheim, 70599 Stuttgart
Layout table for additonal information
Responsible Party: University of Hohenheim
ClinicalTrials.gov Identifier: NCT03057444    
Other Study ID Numbers: UniHohMet-RSIII-2016
First Posted: February 20, 2017    Key Record Dates
Last Update Posted: October 26, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Hohenheim:
resistant starch type III
butyrate-producing gut bacteria
diabetes mellitus type 2
prediabetes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Prediabetic State
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases